An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

PHASE2CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

April 27, 2017

Primary Completion Date

December 17, 2021

Study Completion Date

December 17, 2021

Conditions
Atherosclerotic Cardiovascular DiseaseSymptomatic AtherosclerosisType2 DiabetesFamilial Hypercholesterolemia
Interventions
DRUG

Inclisiran

Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

DRUG

Evolocumab

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.

Trial Locations (52)

10029

Novartis Investigative Site, New York

12203

Novartis Investigative Site, Berlin

23294

Novartis Investigative Site, Richmond

32216

Novartis Investigative Site, Jacksonville

37745

Novartis Investigative Site, Greenville

45229

Novartis Investigative Site, Cincinnati

45246

Novartis Investigative Site, Cincinnati

45355

Novartis Investigative Site, Essen

46260

Novartis Investigative Site, Indianapolis

60590

Novartis Investigative Site, Frankfurt

69120

Novartis Investigative Site, Heidelberg

79106

Novartis Investigative Site, Amarillo

80636

Novartis Investigative Site, Munich

V6Z 1Y6

Novartis Investigative Site, Vancouver

R2H 2A6

Novartis Investigative Site, Winnipeg

L6Z 4N5

Novartis Investigative Site, Brampton

N6A 4G5

Novartis Investigative Site, London

M5C 2T2

Novartis Investigative Site, Toronto

G7H 7K9

Novartis Investigative Site, Chicoutimi

H2W 1R7

Novartis Investigative Site, Montreal

J1H 5N4

Novartis Investigative Site, Sherbrooke

G1V 4G5

Novartis Investigative Site, Québec

G1V 4W2

Novartis Investigative Site, Québec

A1B 3V6

Novartis Investigative Site, St. Johns

2333 ZA

Novartis Investigative Site, Leiden

3021 HC

Novartis Investigative Site, Rotterdam

1105 AZ

Novartis Investigative Site, Amsterdam

7416 SE

Novartis Investigative Site, Deventer

5611NJ

Novartis Investigative Site, Eindhoven

4462 RA

Novartis Investigative Site, Goes

7909 AA

Novartis Investigative Site, Hoogeveen

9603 AE

Novartis Investigative Site, Hoogezand

1624 NP

Novartis Investigative Site, Hoorn

2545 CH

Novartis Investigative Site, The Hague

3582 KE

Novartis Investigative Site, Utrecht

3584 CX

Novartis Investigative Site, Utrecht

5912 BL

Novartis Investigative Site, Venlo

3331 LZ

Novartis Investigative Site, Zwijndrecht

PL23 1DT

Novartis Investigative Site, Fowey

PL14 3XA

Novartis Investigative Site, Liskeard

TR18 AJH

Novartis Investigative Site, Penzance

PL26 7RL

Novartis Investigative Site, St Austell

PL11 2TB

Novartis Investigative Site, Torpoint

B15 2TH

Novartis Investigative Site, Birmingham

ED16 4SA

Novartis Investigative Site, Edinburgh

EX2 5DW

Novartis Investigative Site, Exeter

HP16 9QJ

Novartis Investigative Site, High Wycombe

NW3 2QG

Novartis Investigative Site, London

M13 9WL

Novartis Investigative Site, Manchester

NE4 4LP

Novartis Investigative Site, Newcastle Upon Tyme

PL5 3JB

Novartis Investigative Site, Plymouth

WR5 1DD

Novartis Investigative Site, Worcester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY